Balchem Corp. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Balchem Corporation on September 20, 2005, reporting events that occurred on September 16, 2005. The filing details the entry into a material definitive agreement regarding executive compensation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to the terms of stock option grants:
- Exercise Price: $31.07 per share.
- Total Options Granted: 118,000 shares.
Material Changes and Executive Grants
The Board of Directors granted stock options to six executive officers under the Company's 1999 Stock Plan. The specific allocations are as follows:
- Dino Rossi: 40,000 shares
- Francis Fitzpatrick: 30,000 shares
- David Ludwig: 24,000 shares
- Robert Miniger: 9,000 shares
- Paul Richardson: 10,000 shares
- Matthew Houston: 5,000 shares
Vesting Schedule: 20% on the first anniversary, 40% on the second anniversary, and 40% on the third anniversary of the grant date.
Expiration: All options expire on September 15, 2015.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard terms of the stock option agreement.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 1999 Stock Plan to assess remaining capacity for future grants.
- Confirm the market price of Balchem stock on September 16, 2005, to evaluate the "in-the-money" status of the $31.07 exercise price.
- Review the Company's most recent 10-K or 10-Q for the impact of these grants on diluted earnings per share.